

Exceptional outcomes. *Proven again.*



Japan IDE Clinical Study Results: Proven patency in complex SFA lesions.

88% 12-month primary patency in long, complex SFA lesions (n = 103)¹

- 21.8 cm average lesion length
- 65.7% chronic total occlusions (CTOs)
- 84.5% TASC II C&D lesions



12-Month Patencies: GORE® VIABAHN® Endoprosthesis Japan IDE Clinical Study*



* GORE® VIABAHN® Endoprosthesis Japan IDE Clinical Study demonstrated 12-month primary patency of 92% as defined by evidence of flow with no Target Lesion Revascularization (TLR). The same study demonstrated 88% 12-month primary patency when defined by PSVR of < 2.5 without a TLR.


Proven Patency for Complex SFA Lesions.

359 Limbs Studied

255 CTOs

21 cm Average Lesion Length*

78% Average Primary Patency**



STUDY	NUMBER OF LIMBS	LESION LENGTH (cm)	CTOs (%)	12-MONTH PRIMARY PATENCY	12-MONTH SECONDARY PATENCY
Japan IDE Clinical Study ¹	103	22	66	88	98
Gore VIPER Clinical Study ²	119	19	56	73	92
VIASTAR Trial ³	66	19	79	78	90
25 cm Trial ⁴	71	27	93	67	97
Combined Results (Weighted average, as appropriate)	359	21	70	78	94

Read the Japan IDE Clinical Study Abstract at goremedical.com/ap/viabahn

* Weighted Average Lesion Length

** 12-Month Weighted Average Primary Patency

1. Ohki T, Kichikawa K, Yokoi H, *et al.* Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. *Journal of Vascular Surgery* 2017;66(1):130-142.e1.
2. Saxon RR, Chervu A, Jones PA, *et al.* Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) Trial. *Journal of Vascular & Interventional Radiology* 2013;24(2):165-173.
3. Lammer J, Zeller T, Hausegger KA, *et al.* Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). *Journal of the American College of Cardiology* 2013;62(15):1320-1327.
4. Zeller T, Peeters P, Bosiers M, *et al.* Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm Trial. *Journal of Endovascular Therapy* 2014;21(6):765-774.



W. L. GORE & ASSOCIATES, INC.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com

Products listed may not be available in all markets.

GORE®, VIABAHN®, and designs are trademarks of W. L. Gore & Associates. © 2017 W. L. Gore & Associates, Inc. AW1471-EN1 NOVEMBER 2017

 Consult Instructions for Use